



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: 2/20/03

Signature: *Anna P. Lucey*

(Anna P. Lucey)

RECEIVED
FEB 27 2003
TECH CENTER (PATENT)
Docket No.: AIA P03-0023
(P03-0023)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Madiyalakan

Application No.: 09/994466

Group Art Unit: 1614

Filed: November 26, 2001

Examiner: N/A

For: THERAPEUTIC BINDING AGENTS
AGAINST MUC-1 ANTIGEN AND
METHODS FOR THEIR USE

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
Washington, DC 20231

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents should one or more of the documents be applied against the claims of the current application.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 18-1945, under Order No. AREX-P03-002.

Dated:

Respectfully submitted,

By

Matthew P. Vincent

Registration No.: 36,709

ROPES & GRAY

One International Place

Boston, Massachusetts 02110-2624

(617) 951-7000

(617) 951-7050 (Fax)

Attorneys for Applicant

INFORMATION DISCLOSURE CITATION

IN AN APPLICATION

(Use several sheets if necessary)

Docket Number (Optional)

AREX-P03-002

Application Number
09/994,466

Sheet Page 1 of 2

FEB 27 2003

Applicant

Madiyalakan

Filing Date

November 26, 2001

Group Art Unit
1614

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,506,343	4/9/96	Kufe		

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

AB	Burchell, J. et al. Detection of the Tumour-Associated Antigens Recognized by the Monoclonal Antibodies HMFG-1 and 2 in Serum From Patients with Breast Cancer. Int. J. Cancer 34, 763-768 (1984).
AC	Burchell, J. et al. Active Specific Immunotherapy: PEM as a Potential Target Molecule. Cancer Surv. 18, 135-148 (1993).
AD	Codington, J.F. and Frim, D.M. "Cell-Surface Macromolecular and Morphological Changes Related to Allotransplantability in the TA3 Tumor" in Biomembranes, L.A. Mansoe, ed. Plenum Pub. Corp., N.Y. p. 207-259 (1983).
AE	Devine, P.L. and Mackenzie, I.F.C. Mucins: Structure, Function, and Associations with Malignancy. BioEssays 14, 619-625 (Sept. 1993).
AF	Gendler, S.J. et al. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. PNAS 84, 6060-6064 (Sept. 1987).
AG	Gendler, S.J. et al. Molecular Cloning and Expression of Human Tumor-associated Polymorphic Epithelial Mucin. J. Biol. Chem. 265, 15286-15293 (5 Sept. 1990).
AH	Ho, S.B. et al. Heterogeneity of Mucin Gene Expression in Normal and Neoplastic Tissues. Cancer Res. 53, 641-651 (1 Feb. 1993).
AI	Hull, S.R. et al. Oligosaccharide Differences in the DF3 Sialomucin Antigen from Normal Human Milk and the BT-20 Human Breast Carcinoma Cell Line. Cancer Commun. 1, 261-267 (1989).
AJ	Jentoff, N. Why are proteins O-glycosylated? TIBS 15, 291-294 (Aug. 1990).
AK	Lightenberg, M.J.L. et al. Episialin, a Carcinoma-associated Mucin, is Generated by a Polymorphic Gene Encoding Splice Variants with Alternative Amino Termini. J. Biol. Chem. 265, 5573-5578 (5 April 1990).
AL	Linsley, P.S. et al. Elevated Levels of a High Molecular Weight Antigen Detected by Antibody W1 in Sera from Breast Cancer Patients. Cancer Res. 46, 5444-5450 (Oct. 1986).

Form PTO/SB/08

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**
(Use several sheets if necessary)
Docket Number (Optional)
AREX-P03-002Application Number
09/994,466Applicant
MadiyalakanGroup Art Unit
1614Filing Date
November 26, 2001

Magnani, J.L. et al. Identification of the Gastrointestinal and Pancreatic Cancer-associated Antigen Detected by Monoclonal Antibody 19-9 in the Sera of Patients as a Mucin. Cancer Res. 43, 5489-5492 (Nov. 1983).

Metzgar, R.S. et al. Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. PNAS 81, 5242-5246 (Aug. 1984).

AO Miller, S.C. et al. Ultrastructural and Histochemical Differences in Cell Surface Properties of Strain-Specific and Nonstrain-Specific TA3 Adenocarcinoma Cells. J. Cell Biol. 72, 511 (1977).

AP Neutra, M.R. and Forstner, J.F. "Gastrointestinal Mucus: Synthesis, Secretion, and Function" in Physiology of the Gastrointestinal Tract, 2nd edition, L.R. Johnson, ed. Raven Press, N.Y. p. 975-7009 (1987).

AQ Parry, G. et al. Determination of Apical Membrane Polarity in Mammary Epithelial Cell Cultures: The Role of Cell-Cell, Cell-Substratum, and Membrane-Cytoskeleton Interactions. Exp. Cell Res. 188, 302-311 (1990).

AR Pihl, E. et al. Mucinous Corectal Carcinoma: Immunopathology and Prognosis. Pathol. 12, 439-437 (1980).

AS Regimbald, L.H. et al. The Breast Mucin MUC1 as a Novel Adhesion Ligand for Endothelial Intercellular Adhesion Molecule 1 in Breast Cancer. Cancer Res. 56, 4244-4249 (15 Sept. 1996).

AT Rittenhouse, H.G. et al. Mucin-Type Glycoproteins as Tumor Markers. Lab Med. 16, 556-560 (Sept. 1985).

AU Siddiqui, J. et al. Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. PNAS 85, 2320-2323 (April 1988).

AV Wong, R.C.K. et al. Signal Transduction via Leukocyte Antigen CD43 (Sialophorin): Feedback Regulation by Protein Kinase C1. J. Immunol. 144, 1455-1460 (15 Feb. 1990).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

RECEIVED
FEB 27 2003
TECH CENTER 1600/2000